Banner News

Singapore, July 26, 2022 – Credo Diagnostics presents at AACC, Chicago, IL, USA, on July 26 - 28, 2022.


At the 2019 AACC in Anaheim, CA, Booth #4339, Credo Diagnostics launched our VitaPCR™ Instrument and our first VitaPCR™ Influenza A&B Assay.


After one year, our product lines include the VitaPCR™ SARS-CoV-2 Gen 2 Assay, VitaPCR™ Influenza/SARS-CoV-2 Assay, VitaPCR™ Influenza/RSV Assay, and VitaPCR™ Strep A Assay.
For AACC 2022 in Chicago, Credo Diagnostics are happy to announce our participation, and importantly, will introduce our new molecular diagnostic platform – VitaSIRO solo™, and share what we have done since the onset of COVID-19 to help countries provide VitaPCR™ machines.


“Today, it is a great honour to see our solutions accepted and requested by users worldwide. We strive to provide the best solutions to our customers continually and we will never stop innovating."

Come visit us at Booth #4456 to see for yourself.


Credo Diagnostics, “Advanced Medical Technology For All”


AACC firstday

 Booth #4456, 2022 AACC Annual Scientific Meeting & Clinical Lab Expo


About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.


We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.